John Shomberg, Ph.D., who was the lead author on the publication and is Director of the Bioinformatics team at Afecta, stated that, “This study on again demonstrates our computational platforms’ unique and powerful capability to apply advanced machine learning to complex biological datasets. We are looking forward to the next step in this project. Using the chemical biology algorithms in PharmetRx we also have been able to identify key molecular features of Luteolin that provide its mechanism of action and design a series of new compounds that are likely to be even more effective”. Importantly in looking at our recent data it appears that in addition to malignant melanoma several other tumor types are inhibited.
According the Feng Liu-Smith, Ph.D., the principle investigator at UCI, “Melanoma is the most serious type of skin cancer and the most difficult to treat. It often spreads to other sites in the body very early on. When this happens, it can be difficult to treat, and the outlook is often very poor. We are looking forward to testing the new compounds that have been created.”
Afecta Pharmaceuticals has previously applied the PharmetRx platform to development other new treatments for serious disorders affecting the eyes, central nervous system, skin and others. Their work has sparked interest from companies like Allergan, Supernus, AstraZeneca and others. They also collaborate with a number of universities in the US and abroad to create new therapeutics.
About Afecta Pharmaceuticals
Afecta Pharmaceuticals is a privately held drug discovery and development company that leverages several key technologies and is positioned to change the pharmaceutical paradigm through innovation.